initial public offerings (IPOs) trading on American exchanges

Saturday, January 31, 2015

Spark Therapeutics (ONCE) began trading on the NASDAQ on 30 January 2015




Description

Spark Therapeutics, Inc. is engaged in the field of gene therapy. The Company develops one-time, life-altering treatments for patients suffering from debilitating genetic diseases. The Company is focused on treating rare diseases where no, or only palliative therapies exist. The Company addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Its pipeline of product candidates is based on AAV vector technology. The Company’s product candidate, SPK-RPE65, is in a Phase III clinical trial for the treatment of inherited retinal dystrophies (IRDs) caused by mutations in the RPE65 gene. It is also conducting other preclinical programs such as SPK-CHM, SPK-FIX and GenableRhoNova. The Company has received both breakthrough therapy and orphan product designation for SPK-RPE65 and orphan product designation for SPK-CHM for the treatment of choroideremia.

Address

3737 Market St Ste 1300
PHILADELPHIA, PA 19104-5543
United States 

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-33.72%-
Return on average equity--
Employees47

Angie's List (ANGI) : 3-year performance

weekly


daily

Thursday, January 29, 2015

Workiva (WK), 2-month performance


CommScope (COMM) : 1-year performance

weekly

daily

YuMe (YUME) : 18-month performance

  • In September 2017, YuMe Inc was acquired by San Francisco ad tech company RhythmOne LLC for $185 million.  The combined programmatic ad exchange RhythmOne plus video ad platform YuMe will reach about 220 million visitors monthly.

weekly


daily

Sunday, January 25, 2015

Nevro (NVRO) began trading on the NASDAQ on 6 November 2014


Description

Nevro Corp. is a medical device company focused on developing solutions in the neuromodulation space. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. The Company’s High-frequency spinal cord stimulation (SCS) system, the HF10 SCS, is a spinal cord simulation therapy, which provides electric pulses at a rate of approximately 10,000 Hz for spinal cord stimulation in the treatment of chronic back and leg pain. The electrical pulses are conveyed by small electrodes placed in the epidural space and connected to a battery-powered generator implanted under the skin. The Nevro Senza SCS system is available in Europe and Australia. It is undergoing a pivotal clinical trial, which is intended to collect data to support an application for a Nevro Senza implantable spinal cord stimulation system. The Company’s SENZA-RCT study is intended to evaluate the safety and effectiveness of the Senza SCS system.

Address

4040 Campbell Ave Ste 210
MENLO PARK, CA 94025-1053
United States 

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin-90.97%-110.70%
Operating margin-74.97%-107.03%
EBITD margin--106.83%
Return on average assets-53.15%-41.78%
Return on average equity--
Employees114

Springleaf (LEAF) : 1-year performance

The company was formerly known as Springleaf Holdings (LEAF) and changed its name to OneMain Holdings (OMF) in November 2015.  In March 2015, Springleaf entered into an agreement to acquire OneMain Financial from Citigroup for $4.25 billion.
    

10-months, daily

weekly

Juno Therapeutics (JUNO) began trading on the NASDAQ on 19 December 2014



Description



Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. The Company’s CD19 product candidates include JCAR015, JCAR017, and JCAR014. Its additional product candidates include CD22, L1CAM, MUC-16/IL-12, ROR-1 and WT-1.

Address

307 Westlake Ave N Ste 300
SEATTLE, WA 98109-5235
United States 

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-48.60%-
Return on average equity--
Employees70

Saturday, January 24, 2015

Friday, January 23, 2015

Box (BOX) began trading on the NYSE on 23 January 2015

Box (NYSE:BOX), a provider of online storage and file-sharing services, popped 66% on its first day of trading, raising $175 million. The debut is expected to fuel enthusiasm for other high-profile new issues this year.

Box stock priced at 14, above the estimated range, and sold 12.5 million shares. The stock peaked at 24.73 and closed at 23.23. The strong performance came despite Box showing huge losses on the bottom line.


Box's founders, CEO Aaron Levie and CFO Dylan Smith, take turns striking a ceremonial bell Friday at the New York Stock Exchange.


30-year-old Box CEO Aaron Levie

Fast Growth, Big Losses
Box revenue rose 80% to $153.8 million for the nine months ended Oct. 31. But the company lost a net $121.5 million. Box spent $152.4 million on sales and marketing in that span, up 23% from a year earlier. Another $48.4 million went for research and development, up 49%.
Box says its annual recurring revenue — the value of subscription contracts likely to recur over 12 months — is $225 million .

Box is spending heavily to draw in more customers, with the idea being it will turn profitable down the road. It's a recurring theme for tech IPOs.

Box says it has more than 44,000 paying corporate customers or organizations and 32 million registered users. The basic service is free, with fees charged for premium services.

In its IPO road show to institutional investors, Box presented a long-term outline for profitability, said Francis Gaskins, founder of IPOdesktop.com and research director for Equities.com.

Another reason for investor enthusiasm is Box's transition from data storage into the broader field of enterprise content management, a category with huge market potential.
"Box is losing money now, but their long-term financial goal is 20%-to-25% free cash flow on revenue," he said.

Boxed In By Rivals?
Box was the first IPO of a company in its category, albeit one with many rivals. They include Amazon (NASDAQ:AMZN), Google (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT) and Dropbox, which is expected to IPO this year.

Eleven new issues are planned for the week of Jan. 26, expected to raise about $1 billion. That's the most in one week since the 13 IPOs in the first week of October that raised $2.9 billion, according to IPO research firm Ipreo.

Among the IPOs coming is Shake Shack, which looks to raise $75 million. The fast-casual burger chain will follow Habit Restaurants (NASDAQ:HABT), which popped 120% on its Nov. 20 debut, closing at 40.25. The stock priced at 18 and currently trades near 30.

Another closely watched IPO in the coming week is Spark Therapeutics, which is developing gene therapies for retinal dystrophies and hematologic disorders. It plans to raise $88 million.
Nine of the 11 IPOs slated for the coming week are in the health care field, maintaining the hot streak from 2014.

Last year was the best IPO market since 2001. The year ended with 273 IPOs, up 23% from the prior year, according to Renaissance Capital. Proceeds leaped 55% to $85 billion, led by Alibaba (NYSE:BABA), which raised $22 billion in its record-setting IPO.


Sunday, January 18, 2015

Karyopharm Therapeutics (KPTI) : 1-year performance

** weekly **


** daily **


CHC Group (HELI) : 1-year performance


  • On 5 May 2016, CHC Helicopters filed for Chapter 11 Bankruptcy.  CHC shares dropped from US$176.10 (17th Nov 14) to US 0.45cents 17 June 2016. A Texas court allowed CHC in July 2016 to shed 65 helicopters from its financial obligations, most of the Super Pumas.  CHC reorganized in March 2017.

** daily **


** weekly **